During the last three months, 4 analysts shared their evaluations of Moderna (NASDAQ: MRNA ), revealing diverse outlooks from ...
Breakthrough technology that transforms the body into a virus-zapping vaccine factory is poised to revolutionise the fight against COVID-19 but future pandemics and even cancer could be next, ...
Swiss contract drug manufacturer Lonza's plants in the United States and Switzerland are due to make ingredients for 400 million doses of Moderna's COVID-19 vaccine annually, Lonza said on Monday.
StockStory.org on MSN
10x Genomics, BioMarin Pharmaceutical, AMN Healthcare Services, Illumina, and Moderna Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by ...
Quantum computing is already breaking out of the lab and proving its worth in the real world. The Nobel win reveals India is on the right track.
By casting doubt about the promise of mRNA tech, RFK Jr. is slowing progress toward highly effective therapies that could ...
While tariff threats and drug pricing pressures weighed on healthcare stocks' outlook, some parts of the sector are beginning to stage a recovery. TD Asset Management's Ram Sampath discusses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback